Previous Close | 10.55 |
Open | 10.45 |
Bid | 10.52 x 400 |
Ask | 10.58 x 600 |
Day's Range | 10.43 - 10.87 |
52 Week Range | 4.26 - 16.90 |
Volume | |
Avg. Volume | 1,042,887 |
Market Cap | 578.679M |
Beta (5Y Monthly) | 0.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Astria Therapeutics Inc (NASDAQ:ATXS), a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat debilitating diseases, has reported an insider sale according to a recent SEC filing.
Key Insights Significantly high institutional ownership implies Astria Therapeutics' stock price is sensitive to their...
Christopher Morabito, Chief Medical Officer of Astria Therapeutics Inc (NASDAQ:ATXS), has sold 10,000 shares of the company on January 29, 2024, according to a recent SEC Filing.